The startup develops small molecule therapeutics that selectively disrupt hunger signaling to regulate energy homeostasis, providing an oral treatment for obesity and rare genetic metabolic diseases. This approach enables effective management of obesity-related conditions while preserving nutrient absorption, offering a safe therapeutic option for clinicians.

AdvanCell is a clinical-stage radiopharmaceutical company developing targeted alpha therapies using proprietary ²¹²Pb production technology to treat various cancers, including prostate and pancreatic. This approach aims to enhance patient survival and quality of life by delivering precise radiation to tumor cells while minimizing damage to surrounding healthy tissue.

Aeovian Pharmaceuticals is developing AV078, a selective mTORC1 inhibitor designed to treat refractory epilepsy associated with tuberous sclerosis complex (TSC), a rare genetic disorder characterized by hyperactive mTORC1 signaling. The company aims to provide a targeted therapeutic option that improves safety and efficacy compared to existing nonselective mTOR inhibitors, addressing the significant unmet medical need in managing TSC-related seizures.

Alebund Pharmaceuticals develops targeted biopharmaceutical therapies for renal diseases, utilizing advanced drug formulation techniques to enhance treatment efficacy. The company focuses on addressing the unmet medical needs of patients suffering from chronic kidney conditions, aiming to improve their quality of life through effective therapeutic options.

Attivare Therapeutics develops the ATTImmune platform, a biomaterial scaffold that creates a localized microenvironment to recruit, activate, and reprogram immune cells at tumor sites. By loading the scaffold with customizable immunomodulators such as cytokines, CpG or mRNA, the platform delivers 3D spatiotemporal control of immune activation, enhancing the magnitude and durability of anti‑tumor responses for low‑immunogenic cancers and potentially infectious diseases.

BIOS Health develops neural interfaces and AI technology to read and write neural data, enabling real-time analysis of the nervous system's signals. This approach addresses the malfunctioning signals that can lead to diseases, facilitating the creation of targeted pharmaceuticals and software-delivered therapies.

Clene Nanomedicine develops catalytically-active nanocrystals that target cellular energy impairments in neurodegenerative diseases, aiming to restore and protect neuronal health. Their therapeutics address the critical need for effective treatments in a field with limited options for patients suffering from these conditions.

DermBiont develops targeted small molecule therapeutics and biotherapeutics to treat skin diseases by addressing the underlying causes, such as microbiome imbalances. Their pipeline includes treatments for conditions like seborrheic keratosis, hyperpigmentation, atopic dermatitis, tinea pedis, and onychomycosis.

Edgenesis provides Kubernetes-native IoT and edge AI solutions that enhance interoperability and scalability for industrial applications. The platform enables efficient device management and data integration, optimizing production processes while reducing operational costs across various sectors, including agriculture and logistics.

Endeavor BioMedicines is developing ENV-101, a Hedgehog signaling pathway inhibitor, for the treatment of idiopathic pulmonary fibrosis (IPF), aiming to improve lung function and reverse key measures of lung fibrosis. The company also offers ENV-501, an HER3-targeted antibody-drug conjugate designed to treat HER3-positive solid tumors, addressing critical needs in oncology.

Ensoma develops one-time, off-the-shelf, in vivo treatments that utilize advanced hematopoietic stem cell engineering to precisely modify cells within the hematopoietic system. This technology aims to provide durable cures for genetic, immune, and oncological diseases by addressing the limitations of traditional therapies that often require multiple treatments.

Enterome develops off‑the‑shelf peptide immunotherapies that use bacterial peptides mimicking tumor antigens to activate pre‑existing CD8⁺ effector memory T cells. The OncoMimics™ platform selects high‑affinity, non‑self peptides from a gut‑microbiome database and delivers them as stable, room‑temperature subcutaneous injections, which can be combined with standard oncology agents. Phase 2 data across multiple cancer types show rapid, durable responses with a benign safety profile.

Evommune develops novel therapeutics targeting the root causes of chronic inflammatory diseases, utilizing specific antagonists like MRGPRX2 to halt disease progression and alleviate symptoms. The company aims to improve patient outcomes by advancing a clinical-stage pipeline that addresses the debilitating effects of chronic inflammation.

F2 provides an AI platform specifically designed for private market investors to accelerate the investment decision process. The platform automates financial analysis by integrating proprietary institutional knowledge with live market data to uncover risks and validate assumptions. It enables teams to collaborate in real time and generate audit-ready, IC-ready reports quickly from data rooms.

Finch Therapeutics develops microbiome-based therapeutics aimed at addressing serious unmet medical needs through insights gained from human microbiota transplantation studies. The company has established a robust intellectual property portfolio that supports a range of therapeutic applications in the microbiome field.

Kernalbio develops mRNA therapies that enable selective translation of therapeutic proteins in target cells, utilizing a clinically validated delivery system to enhance tissue specificity. This approach addresses the limitations of traditional mRNA design, which often fails to effectively target specific cells within tissue and tumor microenvironments.

The startup is developing a personalized cognitive rehabilitation platform that utilizes neuroplasticity principles to enhance recovery for patients with neurodegenerative diseases. By digitally mapping brain responses, the company aims to create targeted therapeutic interventions that improve patient outcomes and accelerate the development of new treatments.

one.bio develops proprietary processes to integrate active WholeFibers™ back into food products. This technology restores beneficial, hard-to-eat plant fibers often removed during food processing. The company provides a convenient, flavorless method for consumers to increase daily active fiber intake for improved gut health.

The startup develops cell-penetrating mini proteins (CPMPs) that target and neutralize cancer-causing proteins within cancer cells, providing a new therapeutic approach beyond the capabilities of traditional treatments. This technology enables more effective intervention in cancer-related diseases by directly addressing the proteins responsible for tumor growth.

Paradox offers a conversational recruiting platform that automates repetitive tasks such as candidate screening, interview scheduling, and onboarding, enabling hiring teams to focus on meaningful interactions. This technology reduces the time to hire significantly, allowing organizations to streamline their recruitment processes and enhance candidate experiences.

Sanegene Bio develops a proprietary RNA interference (RNAi) drug discovery platform, LEAD™, which enables precise delivery of RNAi therapeutics to liver and extrahepatic tissues. The platform addresses unmet clinical needs across various therapeutic areas, including cardiovascular, metabolic, and immunology-related diseases.

Seismic Therapeutic develops machine-learning algorithms specifically designed for biologics drug discovery in the field of immunology, focusing on autoimmune diseases. Their IMPACT platform enhances the efficiency of identifying and optimizing novel therapeutic candidates, addressing the slow and costly traditional drug development processes.

Siolta Therapeutics develops targeted live biotherapeutics using its Precision Symbiotics Platform™ to create therapeutic microbial consortia that address inflammatory diseases. The company combines clinical data and microbial science to target disease-specific mechanisms, aiming to meet the high unmet medical needs in this area.

Solve Therapeutics develops Antibody Drug Conjugates and Bispecific Therapeutics to target and eliminate cancer cells while minimizing damage to healthy tissue. Their approach addresses the need for more effective and less toxic cancer treatment options in the biopharmaceutical landscape.